DOCSLIB.ORG

Pimozide for Schizophrenia Or Related Psychoses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pimozide for Schizophrenia Or Related Psychoses Pimozide for schizophrenia or related psychoses Item Type Article Authors Rathbone, John Citation Rathbone, J. & McMonagle, T. (2007). Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews, (4), pp.1-220. Download date 24/09/2021 12:35:26 Link to Item http://hdl.handle.net/20.500.12904/9895 Cochrane Database of Systematic Reviews Pimozide for schizophrenia or related psychoses (Review) Mothi M, Sampson S Mothi M, Sampson S. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD001949. DOI: 10.1002/14651858.CD001949.pub3. www.cochranelibrary.com Pimozide for schizophrenia or related psychoses (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 Figure1. ..................................... 8 OBJECTIVES ..................................... 8 METHODS ...................................... 8 Figure2. ..................................... 15 RESULTS....................................... 16 Figure3. ..................................... 17 Figure4. ..................................... 23 Figure5. ..................................... 24 Figure6. ..................................... 31 ADDITIONALSUMMARYOFFINDINGS . 39 DISCUSSION ..................................... 50 AUTHORS’CONCLUSIONS . 52 ACKNOWLEDGEMENTS . 53 REFERENCES ..................................... 54 CHARACTERISTICSOFSTUDIES . 61 DATAANDANALYSES. 120 Analysis 1.1. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 1 Global state: 1. Relapse - clinical diagnoses. 134 Analysis 1.2. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 2 Global state: 2. No improvement. 135 Analysis 1.3. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 3 Mental state: 1. Specific symptoms. 136 Analysis 1.4. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 4 Adverse effects: 1. Extrapyramidal adverse effects. .................................... 137 Analysis 1.5. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 5 Adverse effects: 2. Anticholinergic effects. 139 Analysis 1.6. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 6 Adverse effects: 3. Cardiovascular effects. 140 Analysis 1.7. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 7 Adverse effects: 4. Abnormal laboratory tests. 141 Analysis 1.8. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 8 Adverse effects: 5. Central nervous system effects. .................................... 142 Analysis 1.9. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 9 Adverse effects: 6. Dermatological effects. 143 Analysis 1.10. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 10 Adverse effects: 7. Endocrine effects. 143 Analysis 1.11. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 11 Adverse effects: 8. Gastrointestinal effects. 144 Analysis 1.12. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 12 Adverse effects: 9. Other. 145 Analysis 1.13. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 13 Leaving the study early: 1. Due to adverse effects. .................................... 147 Analysis 1.14. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 14 Leaving the study early: 2. Any reason. 148 Analysis 2.1. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 1 Global state: 1. Relapse - clinicaldiagnoses. 149 Analysis 2.2. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 2 Mental state: 1. Use of additional medication. 149 Analysis 2.3. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 3 Adverse effects: 1. Death. 150 Analysis 2.4. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 4 Leaving the study early: 1. Any reason. .................................... 150 Analysis 3.1. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 1 Service utilisation: 1. Hospital admission.................................... 151 Analysis 3.2. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 2 Global state: 1. Relapse - clinical diagnoses. ................................... 152 Analysis 3.3. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 3 Global state: 2. No improvement................................... 153 Pimozide for schizophrenia or related psychoses (Review) i Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 3.4. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 4 Global state: 3. Average score - CGI(high=poor)................................. 154 Analysis 3.5. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 5 Mental state: 1. Average score - BPRS(high=poor). .. ... ... ... ... ... ... ... ... ... .. 154 Analysis 3.7. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 7 Mental state: 3. No improvement................................... 155 Analysis 3.8. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 8 Mental state: 4. Specific symptoms.................................... 156 Analysis 3.9. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 9 Mental state: 5. Use of additional medication. .................................. 157 Analysis 3.10. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 10 Adverse effects: 1. Extrapyramidal adverseeffects-specific. 158 Analysis 3.12. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 12 Adverse effects: 3. Death. 163 Analysis 3.13. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 13 Adverse effects: 4. Anticholinergic effects. .................................... 164 Analysis 3.14. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 14 Adverse effects: 5. Cardio- vasculareffects. ... ... ... ... ... ... ... ... ... ... .. 166 Analysis 3.15. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 15 Adverse effects: 6. Abnormal laboratorytests. ... ... ... ... ... ... ... ... ... ... .. 169 Analysis 3.16. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 16 Adverse effects: 7. Central nervoussystemeffects.. 171 Analysis 3.17. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 17 Adverse effects: 8. Dermatological effects. .................................... 175 Analysis 3.18. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 18 Adverse effects: 9. Endocrine effects. .................................... 176 Analysis 3.19. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 19 Adverse effects: 10. Gastrointestinaleffects. 177 Analysis 3.20. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 20 Adverse effects: 11. Genitourinaryeffects. 180 Analysis 3.21. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 21 Adverse effects: 12. Other. 181 Analysis 3.23. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 23 Leaving the study early: 1. Due torelapse. ................................... 183 Analysis 3.24. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 24 Leaving the study early: 2. Due toadverseeffects. 184 Analysis 3.25. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 25 Leaving the study early: 3. Any reason. .................................... 185 Analysis 4.1. Comparison 4 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC, Outcome 1 Global state: 1. Relapse - clinical diagnoses. .......... 186 Analysis 4.2. Comparison 4 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC, Outcome 2 Leaving the study early: 1. Any reason. ....... 187 Analysis 5.2. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 2 Global state: 2. Average score - CGI-S (high = poor). ............ 188 Analysis 5.3. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 3 Global state: 3. Average score - CGI-I (high = poor). ............ 188 Analysis 5.4. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 4 Mental state: 1. Average score - BPRS (high = poor). ............ 189 Analysis 5.5. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 5 Mental state: 2. Average score - BPRS psychosis subscale (high = poor). 189 Analysis 5.7. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 7 Mental state: 4. Average score - SANS (high = poor). ............ 190 Analysis 5.8. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 8 Adverse effects: 1. Extrapyramidal adverse effects - specific. .............. 191 Pimozide for schizophrenia or related psychoses (Review) ii Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 5.10. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 10 Adverse effects: 3. Cardiovascular effects. ............. 192 Analysis 5.11. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 11 Adverse effects: 4. Cardiovascular effects - average score (high = poor). 193 Analysis 5.14. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome14Adverseeffects:7.Other. 195 Analysis 5.16. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 16 Leaving the study early: 1. Due to adverse effects. ................ 196 Analysis 5.17. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 17 Leaving the study early: 2. Any reason. .......... 197 Analysis 6.1. Comparison 6 PIMOZIDE + ANY ANTIPSYCHOTIC versus
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,871,778 Kino Et Al
    USOO5871778A United States Patent (19) 11 Patent Number: 5,871,778 Kino et al. (45) Date of Patent: Feb. 16, 1999 54 SUSTAINED RELEASE MICROSPHERE 58 Field of Search ..................................... 424/426, 450, PREPARATION CONTAINING 424/497, 489 ANTIPSYCHOTC DRUG 56) References Cited 75 Inventors: Shigemi Kino; Tomonori Osajima; Hiroaki Mizuta, all of Fukuoka, Japan U.S. PATENT DOCUMENTS 4,994,281 2/1991 Muranishi et al. ..................... 424/497 73 Assignee: Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan Primary Examiner Thurman K. Page ASSistant Examiner Sharon Howard Attorney, Agent, or Firm Sughrue, Mion, Zinn, Macpeak 21 Appl. No.: 812,544 & Seas, PLLC 22 Filed: Mar. 7, 1997 57 ABSTRACT Related U.S. Application Data A Sustained release microSphere preparation which is pro 62 Division of Ser. No. 443,021, filed as PCT/JP93/01673 N duced by including a hydrophobic antipsychotic drug Such 1. g EN's 656.299 eaS OW. as bromperidol, haloperidol or the like into a base composed 2 2 u stus i v w8 - 2 -/- /24 - - - of a high molecular weight polymer having in Vivo histo 30 Foreign Application Priority Data compatibility Such as polylactic acid, poly(lactic-co Nov. 17, 1992 JP Japan 4-332441 glycolic)acid or the like, and a process for the production • - 1 a Pall . thereof. (51) Int. Cl." ....................................................... A61K 9/50 52 U.S. Cl. ........................... 424/489: 424/426; 424/497 8 Claims, 4 Drawing Sheets 2O O EXAMPLE O A EXAMPLE 2 EXAMPLE 3 OO SS SO 8O U 7O 6O CD Z 5O 2. 4O 3O O1 2 O O O 5 2O 25 3O TIME (DAY) U.S.
    [Show full text]
  • Cyclic Antidepressant Drugs SI Conversion: [AUQ: Dr
    834 II: THERAPEUTIC DRUGS 127. Spiker DG, Pugh DD. Combining tricyclic and monoamine oxidase inhibi- 145. Chambost M, Liron L, Peillon D, et al. [Serotonin syndrome during fluoxetine tor antidepressants. Arch Gen Psychiatry 1976;33(7):828–830. poisoning in a patient taking moclobemide.] Can J Anaesth 2000;47(3):246– 128. Peebles-Brown AE. Hyperpyrexia following psychotropic drug overdose. 250. Anaesthesia 1985;40(11):1097–1099. 146. Myrenfors PG, Eriksson T, Sandsted CS, et al. Moclobemide overdose. J 129. Tuck JR, Punell G. Uptake of (3H)5-hydroxytryptamine and (3H)noradrenaline Intern Med 1993;233(2):113–115. by slices of rat brain incubated in plasma from patients treated with chlorimi- 147. Pounder DJ, Jones GR. Post-mortem drug redistribution––a toxicological pramine, imipramine or amitriptyline. J Pharm Pharmacol 1973;25(7):573–574. nightmare. Forensic Sci Int 1990;45(3):253–263. 130. Gillman PK. Successful treatment of serotonin syndrome with chlorproma- 148. Lichtenwalner MR, Tully RG, Cohn RD, et al. Two fatalities involving zine. Med J Aust 1996;165(6):345–346. phenelzine. J Anal Toxicol 1995;19(4):265–266. 131. Graham PM. Successful treatment of the toxic serotonin syndrome with 149. Yonemitsu K, Pounder DJ. Postmortem changes in blood tranylcypromine chlorpromazine. Med J Aust 1997;166(3):166–167. concentration: competing redistribution and degradation effects. Forensic 132. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation fol- Sci Int 1993;59(2):177–184. lowing a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 150. Baselt RC, Shaskan E, Gross EM. Tranylcypromine concentrations and 1987;42(7):760–763.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]